Company*

University/Non-Profit [Scientist]

Type Of Agreement

Product Area

Details (Month)

ACADIA PharmacoGenomics (wholly owned subsidiary of ACADIA Pharmaceuticals Inc.*)

Karolinska Institute CMM (Sweden)

Research collaboration

Pharmacogenomic project in antipyschotic field

Collaboration will compare two patient populations: a group that responds to the traditional anti-psychotic haloperidol, and a group that does not respond to traditional agents but does respond to clozapine; ACADIA's R-SAT platform will analyze genes from patient samples; Karolinksa will provide clinical data (2/00)

Alexion Pharmaceuticals (ALXN)

Brigham and Women's Hospital Inc. [Gregory Stahl]

Collaborative research and license

Complement-mediated inflammation pathway and associated therapeutics

Alexion receives exclusive worldwide rights to the technologies and associated therapeutic products, including an already-identified monoclonal antibody; products would have potential applications in treating atherosclerosis, unstable angina, stroke and other vascular disorders (2/00)

AltaRex Corp. (Canada;TSE: AXO)

National Institutes of Health (NIH)

License

Monoclonal antibody for the treatment of ovarian and other cancers

AltaRex licensed the antibody from NIH to be developed under the company's Antibody-based Immunotherapy technology platform (1/00)

Amersham Pharmacia Biotech (life sciences business of Nycomed Amersham plc [UK; NYSE: NYE.N)]

The SNP Consortium Ltd.

Membership in nonprofit consortium

Construction of a high-quality map of single nucleotide polymorphisms

Amersham committed $3M to the SNP-mapping effort and joined 10 pharmaceutical companies, Motorola Inc. (NYSE:MOT) and IBM (NYSE:IBM) as members of the SNP Consortium (3/00)

AVANT Immunotherapeutics Inc. (AVAN)

Walter Reed Army Institute of Research

Cooperative research and development

Development of an HIV vaccine candidate

AVANT will provide its Therapore-P24 technology to generate immune responses against the HIV genomic sequence; Therapore consists of two bacterial proteins that deliver peptides or proteins into human cells to induce cell-mediated immune responses; AVANT and Walter Reed each will produce a component of the vaccine to be used in a clinical trial that will be run at Walter Reed (1/00)

AVANT Immunotherapeutics Inc. (AVAN)

Walter Reed Army Institute of Research and the National Institutes of Health

Clinical trial collaboration

Peru-15 cholera vaccine

AVANT will collaborate with Walter Reed and NIH on a Phase IIb clinical trial of Peru-15 under a Clinical Trial Agreement signed between AVANT and the National Institute of Allergy and Infectious Disease (1/00)

Aviron (AVIR)

University of Michigan

Amendment to warrant

Intellectual property and technology related to the cold-adapted influenza vaccine and master donor strains of influenza viruses useful in the production of products for vaccination against influenza, such as Aviron's FluMist

Entities agreed to accelerate the issuance of a warrant to the university, which allows it to purchase 340,000 shares of Aviron common stock at $10 per share; as a result, Aviron will record a one-time charge of $10.9M in 1Q:00 (2/00)

Boston Biomedica Inc. (BBII)

Consortium for Plasma Science LLC

Development and commercialization

BBI's Pressure Cycling Technology for the inactivation of pathogens and other infectious agents in human source plasma

Consortium will provide initial funding to cover BBI's research efforts, with subsequent funding contemplated during the first half of 2000 and annually thereafter based on meeting milestones; BBI will pay consortium a royalty on future sales (12/99)

National Institutes of Health, Department of Defense and the European Network for Virological Assessment of New HIV Therapies

Materials Transfer

Viral isolates representing multiple subtypes of HIV-1

BBI receives title and possession of the collection of more than 40 well-characterized HIV-1 subtypes; transfer enables BBI to develop isolates into diagnostic products (2/00)

Chiron Corp. (CHIR)

Australian Red Cross Blood Service

Product use contract

Chiron's nucleic acid testing system to screen blood supplies for hepatitis C and HIV-1 viruses

Combination test, developed and manufactured by GenProbe Inc., is expected to be fully implemented in Australia by mid-2000; Chiron's Australian subsidiary will assist in implementation (12/99)

Diversa Corp. (DVSA)

Bermuda Biological Station for Research Inc.

Bioprospecting

Sample collection from Bermuda's marine habitats

Diversa and BBSR scientists will collect samples, initially focusing on discovery of recombinant biomolecules from symbiotic bacteria living in sponges, tunicates and other marine life (10/99)

Endovasc Ltd. (OTC BB:ENDV)

Stanford University [John Cooke]

License

Nicotine-based, small-molecule angiogenic agent; initial applications include peripheral occlusion arterial disease and transmyocardial laser revascularization (TMLR)

Endovasc gains exclusive worldwide license to the compound; the TMLR application will be pursued in collaboration with Cardiodyne, a subsidiary of Trimedyne (TMED) (3/00)

Genetic Vectors Inc.*

Norwegian Institute of Public Health

Research collaboration

Population-based genetic screening and gene discovery program

Genetic Vectors will supply the systems necessary to continue and expand Norway's genetic screening and gene discovery program for newborns; Genetic Vectors will develop new technologies and products based on genetic information obtained through the program, and will pay the Norwegian Institute royalties on any revenues resulting from co-developed products (2/00)

Genset SA (France; GENXY)

Whitehead Institute for Biomedical Research

Sponsored research and collaboration; patent license

Discovery and characterization of genes involved in obesity and diabetes

Genset will sponsor research at the institute in the fields of interest and receives an exclusive license to Whitehead's U.S. patent titled "DNA Encoding a Novel Serum Protein Produced Exclusively in Adipocytes"; Genset's evaluation of polymorphisms in the gene encoding the protein, as well as other genes in the same pathway, indicate the protein contributes to obesity and Type II diabetes (1/00)

GenVec Inc.*

National Institutes of Health

License

Gene for pigment epithelium-derived factor for the treatment of blindness

GenVec obtained exclusive rights to the gene, which produces an anti-angiogenic protein; the company has provided biological materials to experts in ophthalmology at Johns Hopkins University and other institutions to perform ocular neovascularization studies (2/00)

Genzyme Molecular Oncology (GZMO)

Dana-Farber Cancer Research Institute [Donald Kufe and Jianlin Gong]

License

Dendritic/cancer cell fusion technology, which has potential applications for treating cancer

GMO exclusively licensed the technology for all therapeutic uses; the company is funding a Phase I breast cancer vaccine trial utilizing the technology (3/00)

GMP Companies Inc.*

Eastern Virginia Medical School

License and research collaboration

Islet-neogenesis associated protein gene with potential applications in diabetes treatment and diagnosis

Agreement provides for $6M in research funding over 5 years, as well as a license fee, research milestones and royalties (3/00)

Guilford Pharmaceuticals Inc.

Johns Hopkins University [Solomon Snyder]

License

Serine racemase, a biological target that could be used to develop treatments for neurode-generative diseases; the enzyme appears to block glutamate overstimulation

Guilford obtained an exclusive license to the discovery and corresponding intellectual property; in addition, Guilford acquired a screening system to identify novel inhibitors of serine racemase (2/00)

Immtech International Inc. (IMMT)

University of North Carolina at Chapel Hill [Richard Tidwell and Jed Hall], Duke University [John Perfect], Georgia State University [David Boykin and David Wilson], and Auburn University [Christine Dykstra]

Establishment of Anti-Fungal Consortium of scientists

In vivo testing of dicationic compounds to select lead oral anti-fungal drug candidates

Immtech has an exclusive worldwide license to all anti-fungal compounds developed by the program; the company is working with the consortium to test the top 15 to 20 candidates in vivo; the plan is to select a preclinical compound in 2000, and move a lead drug into clinical development within 12 months (2/00)

Immunex Corp. (IMNX)

University of Washington School of Medicine in Seattle

Research collaboration

Cell Systems Initiative, a scientific discovery program at the University of Washington School of Medicine dedicated to the comprehensive study of the information systems that operate within all living cells

Immunex will provide $2.1M in working capital over three years and will have four of its senior scientists actively collaborating with other CSI researchers (2/00)

ImmunoGen Inc. (IMGN)

State University of New York at Stony Brook [Iwao Ojima]

Research and development collaboration

Development of novel taxane compounds for cancer applications

Joint discoveries will be owned by both parties, and ImmunoGen has an exclusive option to license SUNY Stony Brook's ownership stake; compounds will be used as new effector molecules for ImmunoGen's Tumor Activated Prodrug technology (2/00)

InKine Pharmaceutical Company Inc. (INKP)

Colon Cancer Alliance (CCA)

Sustaining partner agreement

Colon cancer patient advocacy

InKine became a sustaining partner of CCA, a patient advocacy group (2/00)

InSite Vision Inc. (AMEX:ISV)

INSERM (French National Institute of Health and Medical Research) [Garchon]

License and research collaboration

Modifier gene for TIGR (trabecular meshwork inducible glucocorticosteroid response) gene

InSite licensed patent rights for diagnostic and therapeutic applications of TIGR modifier gene, which, like TIGR, has potential utility in diagnosing and treating glaucoma; InSite also signed a research agreement with Garchon (1/00)

Okayama University (Japan) [Toshihiko Matsuo]

License

Oculomedin gene, which may be related to primary open angle glaucoma and other ophthalmic diseases

License includes patent rights for diagnostic and therapeutic applications and developments related to the gene (2/00)

Invitrogen Corp. (IVGN)

Novartis Institute for Functional Genomics

Research collaboration

Advanced cloning technologies and expression systems, including TOPO and Echo System cloning technologies

NIFG will use Invitrogen's technologies to develop new reagents to facilitate its research; Invitrogen receives rights to sell clones and reagents generated by these collaborative efforts to the research community (12/99)

Kinetix Pharmaceuticals Inc.*

Dana-Farber Cancer Institute [William Sellars]

Research collaboration

Profiling of potential anti-cancer inhibitors of Akt, a cellular enzyme that regulates apoptosis

Kinetix will provide Dana-Farber with research funding and access to the company's portfolio of Akt inhibitors for evaluation in Sellars' assays and preclinical models (2/00)

Layton Bioscience*

Children's Medical Center, Boston [Evan Snyder]

Research and development collaboration

Neural stem cell technology

Layton gained exclusive worldwide rights to research and develop applications of the technology (12/99)

Lexicon Genetics Inc.*

The Scripps Research Institute

Research collaboration

Knockout mice

Lexicon will use its homologous recombination technology to generate knockout mice based on an undisclosed gene discovered by Scripps researchers (1/00)

LifeCell Corp. (LIFC)

FACE TO FACE: The National Domestic Violence Project (a program of the American Academy of Facial Plastic and Reconstructive Surgery)

Product donation

AlloDerm (human tissue chemically processed to remove all epidermal and dermal cells, while preserving the remaining bioactive dermal matrix)

LifeCell will donate AlloDerm for procedures conducted under the FACE TO FACE program, which provides complimentary facial reconstructive and plastic surgery to survivors of domestic violence who have suffered facial, head and neck injuries but cannot afford reconstructive treatment (2/00)

Lynx Therapeutics Inc. (LYNX)

Harvard Medical School [George Church and Stephen Kieffer-Higgens]

License

Materials for attaching oligonucleotide tags to polynucleotides such as DNA sequencing templates

Lynx acquired an exclusive worldwide license to the technology (1/00)

Magainin Pharmaceuticals Inc. (MAGN)

Georgetown University Medical Center [Rosemary Higgins]

Research collaboration

Use of Magainin's anti-angiogenic drug squalamine in combination with captopril for diabetic retinopathy

GUMC will conduct research on the utility of the combination therapy under a grant from the Juvenile Diabetes Foundation (1/00)

Maxygen (MAXY)

National Cancer Institute

Cooperative research and development agreement

Development of protein therapeutics for cancer

Three-year collaboration for the development of certain undisclosed proteins using Maxygen's directed molecular evolution technologies; NCI will provide expertise in characterizing and evaluating the proteins for therapeutic potential (2/00)

Myogen Inc.*

University of Texas Southwestern Medical Center at Dallas [Eric Olson and Stephen Grant]

License and research collaboration

Discovery and development of heart failure therapeutics

Myogen receives exclusive rights to a collection of discoveries, patents and future inventions related to heart muscle diseases (2/00)

Ortec International Inc. (ORTC)

Massachusetts Institute of Technology and Tufts University

Research collaboration

Ortec's CCS collagen sponge

Collaboration will use Ortec's collagen sponge as the scaffold for the growth of various types of cells, especially heart tissue, but also striated muscle, nerve, ligament, blood vessels, bone, cartilage and tendon; Ortec will receive worldwide rights to license any technology resulting from the collaboration (12/99)

Oxford BioMedica plc (UK; LSE: OXB)

University of Maastricht [Hennie Hoogenboom]

License

OBAb2, a human antibody for cancer immunotherapy

Oxford BioMedica acquired rights to antibody (12/99)

PE Biosystems (NYSE:PEB)

University of Geneva [Denis Hochstrasser]

Research collaboration

Development of integrated proteomics system

PE gains access to some of the university hospital clinical chemistry laboratory's intellectual property; collaboration announced in conjunction with PE's creation of a Proteomics Research Center (3/00)

PE Biosystems (NYSE:PEB)

University of Washington, Seattle [Ruedi Aebersold]

Research collaboration

Development of new chemistries and technologies for proteomics applications

PE gains exclusive rights to commercialize ICAT (Isotope Coded Affinity Tags) technology developed by Aebersold for the relative quantification of proteins in complex mixtures; ICAT is expected to permit researchers to analyze changes in protein expression profiles by using mass spectrometry collaboration announced in conjunction with PE's creation of a Proteomics Research Center (3/00)

Pharsight Corp.*

Duke Clinical Research Institute

Research and development collaboration

Development of database resources for use with Pharsight's Clinical Workbench Internet-based system

Pharsight will add DCRI's anonymized data on medical histories, disease severity, treatments and clinical outcomes; initial focus is on cardiovascular applications; additional databases for diabetes and other diseases are planned (3/00)

PPGx Inc. (joint venture between Axys Pharmaceuticals [AXPH] and PPD Inc. [PPDI])

Duke University Medical Center

Research collaboration

Pharmacogenomics project initially focused on breast cancer

Scientists from both organizations will work together to identify and screen various candidate genes for single nucleotide polymorphisms in genes that are involved in the metabolism of drugs used in high-dose chemotherapy regimens; breast cancer is initial disease focus (2/00)

Prolifaron Inc.*

The Scripps Research Institute

License

Catalytic antibody technology that can localize the delivery of a cytotoxic drug to a specific cell or cancer type

Prolifaron received an exclusive worldwide license to the technology, which could improve the safety and toxicity profiles of several cytotoxic drugs (1/00)

Proteus S.A.* (France)

Griffith University (Australia) [Bharat Patel]

Research collaboration and license

Development of industrial products such as enzymes and secondary metabolites; research utilizes microorganisms taken from extreme environments

Proteus gains exclusive rights to access a collection of microorganisms of industrial interest for research, development and commercialization of products such as enzymes and secondary metabolites on an exclusive basis; also, a collaboration has been initiated wherein Griffith will prepare new isolates from specific environments to fit Proteus' ongoing screening programs (3/00)

Reprogenesis Inc.*

Children's Hospital, Boston, and the Massachussetts

License

Organ regeneration technology and tissue engineering bladder substitutes Institute of Technology

Reprogenesis gains exclusive license to product and technology, which will become part of the regenerative medicine pipeline of Curis Inc. (created by the merger of Reprogenesis, Creative BioMolecules Inc. [CBMI] and Ontogeny Inc.) (3/00)

Research Corp. Technologies*

University of Michigan at Ann Arbor [William Kelley, Thomas Palella and Myron Levine]

License

Gene transfer system

Research Corp. licensed rights to a viral-mediated gene transfer system; applications include human gene therapy and DNA vaccine, use in transgenic animals, and general research uses and recombinant protein production; Research Corp. is seeking sublicensees (3/00)

Select Therapeutics Inc. (OTC BB:SLPU)

Institut Curie (France)

Expansion and extension of research and development agreement

Cancer vaccine technology relating to antigen presentation to dendritic cells

Select gains exclusive license to option basic intellectual property relating to antigen presentation to dendritic cells (12/99)

Sequenom Inc. (SQNM)

National Cancer Institute

System installation

Sequenom's MassArray system for single nucleotide polymorphism analysis

System installed at NCI's Advanced Technology Center in Gaithersburg, Md. (12/99)

Center for Human Genetics at Boston University School of Medicine

Purchase agreement

Sequenom's Mass Array system for analysis of genetic variations

University entered purchase agreement for the system, which will be used to analyze genetic variations that cause disease or predisposition to disease (2/00)

National Human Genome Research Institute

Equipment installation

Sequenom's MassArray system, which will be used to identify and understand single nucleotide polymorphisms

MassArray system installed following a cooperative research and development agreement executed between Sequenom and NHGRI in 9/99 (1/00)

SignalGene Inc. (TSE:SGI)

McGill University (Canada)

Research collaboration

Role of nuclear receptors in complex genetic diseases, especially obesity and diabetes

SignalGene invested C$0.25M in project to discover drug targets and receives a time-limited option for an exclusive license to any discoveries made under the project (12/99)

SuperGen Inc. (SUPG)

Clayton Foundation for Research, Houston

Licensing and research agreement

Inhaled versions of formulations of camptothecins (including rubitecan) and taxanes (including paclitaxel)

SuperGen gained worldwide rights to inhaled versions of camptothecin (12/99)

Symyx Technologies Inc. (SMMX)

Technology Licensing Company LLC (technology developed at the University of Houston [Richard Wilson III])

License

Portfolio of patents; technology covered includes use of infrared thermal imaging to improve speed and efficiency of screening and optimizing new catalyst formulations

Symyx acquired an exclusive, worldwide license to patent portfolio for use in conjunction with Symyx's core patents (3/00)

Targeted Genetics Corp. (TGEN)

International AIDS Vaccine Initiative and the Children's Research Institute on the campus of Children's Hospital in Columbus, Ohio

Research collaboration

Development of AIDS vaccine

IAVI will provide more than $6M in the first three years of collaboration to to fund development, preclinical and Phase I studies at Targeted Genetics and Children's; IAVI has secured rights to ensure that a successful vaccine will be distributed in developing countries at a reasonable price; Targeted Genetics will have exclusive rights to commercialize the vaccine in industrialized countries (2/00)

Techniclone Corp. (TCLN)

University of Texas Southwestern Medical Center [Phillip Thorpe and Rolf Brekken]

License

Anti-angiogenesis inhibitor called 2C3 and its derivatives

Techniclone exercised option to gain an exclusive worldwide license to the antibody and its derivatives; antibody is designed to inhibit tumor blood vessel growth by targeting vascular endothelial growth factor (1/00)

University of Southern California

License

Permeability enhancing protein (PEP; a segment of interleukin-2)

Techniclone licensed worldwide rights to PEP, covered by U.S. Patent 6,008,319; PEP appears to make tumors more permeable to drugs and is designed to be used in conjunction with Techniclone's Vasopermeation Enhancement Agent technology platform to increase the uptake of chemotherapeutic agents (2/00)

Therion Biologics*

National Cancer Institute [Jeffrey Schlom and Steven Rosenberg]

Cooperative research and development agreement (CRADA)

Development of therapeutic cancer vaccines

Extended existing CRADA for an additional five years; to date, Therion's collaborations with NCI have yielded eight therapeutic cancer vaccines currently in Phase I and II trials (2/00)

Third Wave Technologies*

Sanger Centre (UK)

Research collaboration

Use of Third Wave's Invader technology to construct a high-density single nucleotide polymorphism map of human chromasome 22

Third Wave is developing and providing assays for approximately 2,000 unique SNPs positioned at roughly 40Kb intervals along chromosome 22; initially Sanger will use the SNP panel to type unamplified genomic DNA from a select group of several hundred individuals (1/00)

Viragen Scotland Ltd. (subsidiary of Viragen Europe Ltd.; OTC BB:VERP)

Research arm of Memorial Sloan-Kettering Cancer Center [Alan Houghton, Philip Livingston and Paul Chapman]

Research and development collaboration

Monoclonal antibody treatment for melanoma and certain other cancers; to be tested as monotherapy and in combination with Viragen's Omniferon alpha interferon product

Viragen will work with MSKCC to produce and manufacture a human monoclonal antibody, which MSKCC will then use in clinical trials; MSKCC agreed to underwrite and coordinate Phase I and II trials (12/99)

Vysis Inc. (VYSI)

Yale University [D. Ward]

Patent license

Technology related to flurorescent in situ hybridization

Vysis entered a royalty-bearing, exclusive license agreement covering Yale's European Patent EP 0 444 115 B1, "Chromosomal In Situ Suppression Hybridization" (2/00)

Xanthon Inc.*

Duke University [Mark Grinstaff]

Sponsored research agreement

Development of novel chemistries for attaching oligonucleotides to indium tin oxide (ITO) electrodes

Research will emphasize identification of suitable linkers for attaching DNA to electrodes; Xanthon's development stage expression analysis system utilizes DNA probes attached to ITO electrodes (3/00)

Xenova Group plc (UK; XNVA)

Brunel University (UK) [Robert Newbold]

Research collaboration

Telomerase inhibitors; research to identify mechanims by which telomerase could be inactivated in cancer cells to provoke cell death

Two-year agreement providing Xenova with exclusive access to Brunel's telomerase research; Xenova and Brunel will work together to develop assays for telomerase and related proteins and evaluate small-molecule compounds (2/00)

Notes:

Unless otherwise noted, the stock symbols listed are on the Nasdaq market.

* Privately held company

ND = Not disclosed.

No Comments